Myrtelle

Developing treatments for neurodegenerative diseases targeting oligodendrocytes to address myelin disorders with few or no treatment options. Lead candidate (rAAV-Olig001-ASPA) is a proprietary gene therapy for Canavan’s disease (CD), a fatal genetic disorder resulting in death typically before age 4. Lead candidate (rAAV-Olig001-ASPA) was awarded Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA.